News

Klick Labs has developed a device that records and transmits Parkinson’s Disease tremors so doctors get a sense of what a patient goes through in real time. By showing what a patient experiences, the hope is that the SymPulse Tele-Empathy Device prompts doctors to pay even more attention to patients’ needs,…

Acorda Therapeutics, which recently announced a corporate restructuring, will focus on the late-stage development of its two therapies for Parkinson’s disease, CVT-301 and tozadenant. The news comes after a March 31 ruling by the U.S. District Court in Wilmington, Delaware, invalidated four Acorda patents related to multiple sclerosis therapy Ampyra. Acorda, based in…

The fourth and last patient of the first group in a clinical trial of stem cell transplants in Parkinson’s disease has successfully received the transplant, the International Stem Cell Corporation (ISCO) reported. Researchers are now preparing for the next stage, in which patients will receive a higher number of…

Impax Laboratories is presenting data on its approved Parkinson’s disease treatment, Rytary, as well as findings in a clinical trial assessing a version of this extended-release carbidopa and levodopa mixture (IPX203) in people with advanced disease symptoms, including possible improvements in daily activities and quality of life. The presentations began Sunday and run…

Dancing helps prevent Parkinson’s disease, obesity, dementia, depression and anxiety, says Dr. Patricia Bragg, CEO of organic health company Bragg Live Food Products. “New studies show that dancing increases your memory and helps prevent a wide variety of diseases such as Alzheimer’s,” Bragg said in a press release.

Adamas Pharmaceuticals will make two presentations in Boston this month on ADS-5102 as a treatment for involuntary muscle movements associated with Parkinson’s disease. ADS-5102, a high-dose amantadine therapy, decreases the duration, intensity and debility of the muscle movements, clinical trials have shown. The problems, which range from slight hand tremors to uncontrollable upper…

British pharmaceutical firm Mission Therapeutics will test its potent, selective USP30-targeted inhibitors in stem cell-derived Parkinson’s disease models, as part of research funded by the Michael J. Fox Foundation for Parkinson’s Research (MJFF). Cells maintain healthy mitochondria — the cell’s power generators — by degrading damaged mitochondria in a process known as mitophagy. Defective…